Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis

Luca Bianchi, Ester Del Duca, Marco Romanelli, Rosita Saraceno, Sergio Chimenti, Andrea Chiricozzi*

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Introduction: Psoriasis is a chronic inflammatory skin disease affecting 2–3% of the population. Certain systemic drugs currently available for its treatment could be associated, in the long term, with organ toxicity and adverse events, thus, clinical monitoring throughout treatment is required. Moreover, tolerability issues, parenteral administration, and barriers to patient access, such as high cost and specialist management lead to treatment failure. Areas covered: Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4i). PDE is the major enzyme class responsible for the hydrolysis of cyclic adenosine monophosphate in immune cells (cAMP). With PDE4 inhibition, apremilast works intracellularly to modulate pro-inflammatory and anti-inflammatory mediator production critically involved in psoriasis. The aim of this paper is to focus the attention on apremilast pharmacodynamics effects, its efficacy and safety in treating moderate-to-severe plaque psoriasis. Expert opinion: Apremilast is an effective and well-tolerated option in treating moderate-to-severe plaque psoriasis. Its safety profile and the oral administration offer significant advantages in prescribing apremilast for the treatment of psoriasis, particularly in some subsets of patients.
Lingua originaleEnglish
pagine (da-a)1121-1128
Numero di pagine8
RivistaEXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Volume12
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • Apremilast
  • oral therapy
  • phosphodiesterase-4-inhibitor
  • psoriasis
  • small molecule

Fingerprint

Entra nei temi di ricerca di 'Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis'. Insieme formano una fingerprint unica.

Cita questo